Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/19331
Title: Inflammasome Adaptor ASC Suppresses Apoptosis of Gastric Cancer Cells by an IL18-Mediated Inflammation-Independent Mechanism.
Authors: Deswaerte, Virginie;Nguyen, Paul;West, Alison;Browning, Alison F;Yu, Liang;Ruwanpura, Saleela M;Balic, Jesse;Livis, Thaleia;Girard, Charlotte;Preaudet, Adele;Oshima, Hiroko;Fung, Ka Yee;Tye, Hazel;Najdovska, Meri;Ernst, Matthias;Oshima, Masanobu;Gabay, Cem;Putoczki, Tracy;Jenkins, Brendan J
Affiliation: Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
Department of Pathology and Immunology, University of Geneva School of Medicine, Geneva, Switzerland
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
La Trobe University School of Cancer Medicine, Heidelberg, Victoria, Australia
Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia
Department of Molecular Translational Science, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia
Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia
Division of Rheumatology, University Hospital of Geneva, Geneva, Switzerland
Issue Date: 1-Mar-2018
EDate: 2017-12-27
Citation: Cancer research 2018; 78(5): 1293-1307
Abstract: Inflammasomes are key regulators of innate immunity in chronic inflammatory disorders and autoimmune diseases, but their role in inflammation-associated tumorigenesis remains ill-defined. Here we reveal a protumorigenic role in gastric cancer for the key inflammasome adaptor apoptosis-related speck-like protein containing a CARD (ASC) and its effector cytokine IL18. Genetic ablation of ASC in the gp130F/F spontaneous mouse model of intestinal-type gastric cancer suppressed tumorigenesis by augmenting caspase-8-like apoptosis in the gastric epithelium, independently from effects on myeloid cells and mucosal inflammation. This phenotype was characterized by reduced activation of caspase-1 and NF-κB activation and reduced expression of mature IL18, but not IL1β, in gastric tumors. Genetic ablation of IL18 in the same model also suppressed gastric tumorigenesis, whereas blockade of IL1β and IL1α activity upon genetic ablation of the IL1 receptor had no effect. The specific protumorigenic role for IL18 was associated with high IL18 gene expression in the gastric tumor epithelium compared with IL1β, which was preferentially expressed in immune cells. Supporting an epithelial-specific role for IL18, we found it to be highly secreted from human gastric cancer cell lines. Moreover, IL18 blockade either by a neutralizing anti-IL18 antibody or by CRISPR/Cas9-driven deletion of ASC augmented apoptosis in human gastric cancer cells. In clinical specimens of human gastric cancer tumors, we observed a significant positive correlation between elevated mature IL18 protein and ASC mRNA levels. Collectively, our findings reveal the ASC/IL18 signaling axis as a candidate therapeutic target in gastric cancer.Significance: Inflammasome activation that elevates IL18 helps drive gastric cancer by protecting cancer cells against apoptosis, with potential implications for new therapeutic strategies in this setting. Cancer Res; 78(5); 1293-307. ©2017 AACR.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19331
DOI: 10.1158/0008-5472.CAN-17-1887
ORCID: 0000-0002-6399-1177
PubMed URL: 29282220
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.